Comments
Glenmark Pharma on Thursday said it has received approval from Russia’s Healthcare Ministry to market Momate Rhino metered nasal spray as an over-the-counter (OTC) product for the treatment of seasonal and perennial allergic rhinitis in patients above 18 years of age.
“Russia is an important market for us and we are consistently looking to expand product offerings. We believe OTC is an interesting space and this approval for Momate Rhino nasal spray will help enhance our presence in this segment,” Glenmark Pharmaceuticals Senior Vice President and Head Asia, Russia & CIS region Csaba Kantor said.
Glenmark Pharmaceuticals Vice President and Business Head - Russia - Oxana Pozdnyakova said, allergic rhinitis affects a significant number of people in Russia.
“The approval to market Momate Rhino as an OTC product paves way for the company to widen patient accessibility of this medicine, which is particularly important at the start of the allergy season,” Pozdnyakova said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.